Buy Divis Laboratories, Raymond: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com told CNBC-TV18, "Since we are buying the largecaps through the indices, there are a lot of midcaps which are offering opportunities. Divis Laboratories is coming out of a bear market and is now notching up gains consistently; that should continue."

"It is not just Divis, for example Ajanta Pharma was a buy and that is also doing well. It is coming out of a base. So is Wockhardt, so is Biocon, so, pharmaceutical as a sector is now waking up. I have been talking about how pharmaceutical is finishing its bear market. Today Divis is the stock of choice as we speak."

"The second is Raymond. The stock has been seeing a parabolic rally. That rally for the short term trader is beneficial, it is likely to continue. Remember it is a short term trade, but it is there. Consider buying Raymond," he said.